Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$66.00 -0.8%	$62.01	$47.86 ▼ $107.37	$3.64B	0.28	605,477 shs	506,811 shs
CRSP CRISPR Therapeutics	$41.36 +0.2%	$37.75	$30.04 ▼ $65.39	$3.57B	1.75	1.75 million shs	2.02 million shs
KRYS Krystal Biotech	$137.07 -2.3%	$146.57	$122.80 ▼ $219.34	$3.96B	0.65	304,820 shs	295,086 shs
NITE Nightstar Therapeutics	$29.56 -1.3%	$25.41	$9.59 ▼ $29.55	$991.45M	2.84	185,808 shs	20,960 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	-0.77%	-3.08%	+11.83%	-7.92%	+19.87%
CRSP CRISPR Therapeutics	+0.19%	-1.19%	+16.18%	-1.80%	-36.20%
KRYS Krystal Biotech	-2.32%	+0.09%	+4.32%	-23.59%	-24.67%
NITE Nightstar Therapeutics	-0.98%	+3.72%	-0.83%	+11.98%	+17.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.6084 of 5 stars	3.5	3.0	0.0	0.0	2.8	2.5	0.0
CRSP CRISPR Therapeutics	3.2834 of 5 stars	4.3	2.0	0.0	0.0	2.7	2.5	0.6
KRYS Krystal Biotech	4.538 of 5 stars	3.5	1.0	0.0	4.7	3.5	2.5	1.9
NITE Nightstar Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.33	68.69% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.75	73.48% Upside
KRYS Krystal Biotech	3.00	Buy	$211.13	54.03% Upside
NITE Nightstar Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NITE, KRYS, CRSP, and ACLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00
5/20/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00
5/20/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/9/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$133.00 ➝ $93.00
5/9/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/8/2025	CRSP CRISPR Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$53.00 ➝ $47.00
5/7/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $81.00
5/7/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $82.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$76.81M	47.35	N/A	N/A	$9.97 per share	6.62
CRSP CRISPR Therapeutics	$35M	102.06	N/A	N/A	$22.52 per share	1.84
KRYS Krystal Biotech	$333.45M	11.88	$3.48 per share	39.38	$32.85 per share	4.17
NITE Nightstar Therapeutics	N/A	N/A	N/A	N/A	$5.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$70.69M	-$2.99	N/A	N/A	N/A	-25.94%	-8.28%	-5.21%	8/14/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-981.54%	-18.46%	-15.79%	8/4/2025 (Estimated)
KRYS Krystal Biotech	$10.93M	$4.16	45.84	13.60	N/A	30.69%	11.41%	10.40%	8/4/2025 (Estimated)
NITE Nightstar Therapeutics	-$36.86M	-$1.26	N/A	N/A	N/A	N/A	-30.89%	-27.65%	N/A

Latest NITE, KRYS, CRSP, and ACLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
NITE Nightstar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.29	4.29
CRSP CRISPR Therapeutics	N/A	22.07	22.07
KRYS Krystal Biotech	N/A	7.28	7.76
NITE Nightstar Therapeutics	N/A	8.54	8.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
CRSP CRISPR Therapeutics	69.20%
KRYS Krystal Biotech	86.29%
NITE Nightstar Therapeutics	32.83%

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
CRSP CRISPR Therapeutics	4.30%
KRYS Krystal Biotech	13.70%
NITE Nightstar Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.70 million	Optionable
CRSP CRISPR Therapeutics	473	86.36 million	82.26 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.71 million	Optionable
NITE Nightstar Therapeutics	47	33.54 million	N/A	Not Optionable

NITE, KRYS, CRSP, and ACLX Headlines

Recent News About These Companies

Biogen's ambitions in gene therapy hit by another failed pivotal trial

May 3, 2025 | pharmaphorum.com

Knight Therapeutics: Strong Revenue Growth and Strategic Prospects Justify Buy Rating

November 10, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)

November 9, 2024 | markets.businessinsider.com

Knight Therapeutics price target lowered to C$6.25 from C$6.75 at Stifel

November 9, 2024 | markets.businessinsider.com

Night Market 2024

November 2, 2024 | asiasociety.org

A new crop of anti-snoring innovations are cropping up to save the day (er, night)!

October 11, 2024 | consumeraffairs.com

Windtree Therapeutics $WINT Announces Positive Phase 2b Results In Early Cardiogenic Shock Treatment

October 7, 2024 | msn.com

NITE The Nightview ETF

September 25, 2024 | seekingalpha.com

Q&A: Atsena Therapeutics’ gene therapy for inherited blindness shows promise

September 11, 2024 | statnews.com

Estée Lauder Taps Nicole Richie for New Night Skincare Campaign

August 2, 2024 | beautypackaging.com

As Night Falls

December 25, 2023 | cambridge.org

Night sweats

December 6, 2023 | nhs.uk

How to take great photos at night

November 19, 2023 | nationalgeographic.com

Thank you for supporting The Big Night In

November 12, 2023 | bbc.co.uk

What channel is Thursday Night Football on? Here's who's playing and how to watch, stream

November 7, 2023 | azcentral.com

What channel is Monday Night Football on? Here's who's playing and how to watch, stream

November 4, 2023 | azcentral.com

Bills vs. Giants Sunday Night Football highlights: Buffalo survives for late win

November 1, 2023 | usatoday.com

Thursday Night Football Betting Odds, Props and Predictions

November 1, 2023 | miamiherald.com

Early bird vs. night owl — is one really healthier than the other? Here's what research shows.

October 14, 2023 | yahoo.com

Football Friday Night

September 17, 2023 | kait8.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
By Jeffrey Neal Johnson | May 19, 2025
View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
3 Trades Members of Congress Are Making Right Now
By Chris Markoch | May 23, 2025
View 3 Trades Members of Congress Are Making Right Now
A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
By Gabriel Osorio-Mazilli | June 6, 2025
View A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
By Gabriel Osorio-Mazilli | May 22, 2025
View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
By Jeffrey Neal Johnson | June 13, 2025
View UnitedHealth Stock Dips: Is This a Value Buy Opportunity?

NITE, KRYS, CRSP, and ACLX Company Descriptions

Arcellx NASDAQ:ACLX

$66.00 -0.51 (-0.77%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$66.07 +0.07 (+0.11%)

As of 06/13/2025 07:58 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

CRISPR Therapeutics NASDAQ:CRSP

$41.36 +0.08 (+0.19%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$41.32 -0.03 (-0.08%)

As of 06/13/2025 07:49 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Krystal Biotech NASDAQ:KRYS

$137.07 -3.26 (-2.32%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$137.08 +0.01 (+0.01%)

As of 06/13/2025 05:50 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Nightstar Therapeutics NASDAQ:NITE

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time